Aldeyra Therapeutics (137) Price & Analysis

0 Followers

137 Stock Chart & Stats

€1.26

€0.01(0.73%)

At close: Jul 30 4:00 PM EDT

€1.26

€0.01(0.73%)

Day’s Range― - ―

52-Week Range€0.55 - €4.84

Previous CloseN/A

Volume1.95K

Average Volume (3M)353.00

Market Cap

€34.99M

Enterprise Value€83.54M

Total Cash (Recent Filing)€45.09M

Total Debt (Recent Filing)€143.45K

Price to Earnings (P/E)―

Beta2.86

Next Earnings

May 06, 2027

EPS EstimateN/A

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.39

Shares Outstanding60,326,420

10 Day Avg. Volume100

30 Day Avg. Volume353

Financial Highlights & Ratios

PEG Ratio0.23

Price to Book (P/B)7.03

Price to Sales (P/S)0.00

P/FCF Ratio-9.33

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price Target

€1.79

Price Target Upside41.69% Upside

Rating ConsensusHold

Number of Analyst Covering1

EPS Forecast (FY)-0.3

Revenue Forecast (FY)€1.11M

Bulls Say, Bears Say

Bulls Say

Manageable Annual LeverageModest annual debt relative to equity indicates the company has not relied heavily on borrowing to fund operations. This preserves some financial flexibility for clinical development and regulatory work, although ongoing losses remain an important constraint on that flexibility.

Extended Cash RunwayAn operational cash runway extending into 2029 gives Aldeyra time to pursue regulatory engagement and potential resubmission without an immediately stated funding deadline. That added duration can support a more deliberate development strategy and reduce near-term execution pressure.

Clinical Evidence BaseA nine-trial evidence base, including five trials meeting multiplicity-controlled primary endpoints, provides a substantial clinical foundation for Aldeyra’s regulatory arguments. While approval is not assured, the breadth of evidence supports continued engagement around reproxalap’s potential commercial use.

Bears Say

No Demonstrated RevenueThe absence of reported revenue means Aldeyra has not yet demonstrated commercial demand or a self-funded operating model. Recurring operating and net losses leave future financial performance dependent on successful development, regulatory progress, and eventual product monetization.

Persistent Cash BurnPersistent negative operating and free cash flow show that the business continues to fund operations externally rather than through internally generated cash. The sharp TTM deterioration versus 2025 suggests renewed spending intensity and increases the risk that additional capital will eventually be needed.

FDA Approval SetbackThe Complete Response Letter directly delays potential commercialization of reproxalap and leaves the lead program facing a regulatory hurdle. Aldeyra’s planned dispute process has uncertain timing and outcome, so the setback extends the path to revenue and increases development execution risk.

Aldeyra Therapeutics News

Aldeyra to submit Formal Dispute Resolution Request to FDA for reproxalap

Aldeyra (ALDX) Therapeutics announced intent to submit to the U.S. Food and Drug Administration a Formal Dispute Resolution...

27d ago

ALDX

Aldeyra sees operational cash runway into 2029

Based on reported cash and cash equivalents of $45.1M as of June 30, 2026, Aldeyra (ALDX) updated financial...

27d ago

ALDX

Aldeyra Therapeutics: Neutral Rating Maintained Amid FDA Uncertainty; $2 Price Target Reaffirmed

Analyst Matthew Caufield of H.C. Wainwright reiterated a Hold rating on Aldeyra Therapeutics, retaining the price target of...

26d ago

ALDX

Aldeyra Pursues FDA Dispute Over Dry Eye Drug

Aldeyra Therapeutics ( ($ALDX) ) has issued an update. On September 25, 2026, Aldeyra Therapeutics held a Type...

27d ago

ALDX

Analyst Maintains Hold on Aldeyra Amid FDA Uncertainty Over Reproxalap’s Regulatory Path

Matthew Caufield, an analyst from H.C. Wainwright, reiterated the Hold rating on Aldeyra Therapeutics. The associated price target...

2M ago

ALDX

Aldeyra Therapeutics Leases New Concord Headquarters Space

Aldeyra Therapeutics ( ($ALDX) ) just unveiled an update. On July 28, 2026, Aldeyra Therapeutics executed a lease...

3M ago

ALDX

ALDX Upcoming Earnings Report: What to Expect?

Aldeyra Therapeutics (ALDX) is scheduled to report 2nd quarter earnings on 07/31/2026. Regarding Q2 estimates, Wall Street analysts...

3M ago

ALDX

Aldeyra Therapeutics Adds Independent Director, Affirms Governance Support

The latest update is out from Aldeyra Therapeutics ( ($ALDX) ). On June 9, 2026, following its annual...

5M ago

ALDX

Shareholders Sue Aldeyra Therapeutics Over Dry Eye Drug Claims

A class action lawsuit was filed against Aldeyra Therapeutics ($ALDX) on March 30, 2026. Plaintiffs in the federal...

5M ago

ALDX

Aldeyra Updates Reproxalap Outlook and Extends Cash Runway

The latest update is out from Aldeyra Therapeutics ( ($ALDX) ). On May 1, 2026, Aldeyra Therapeutics released...

6M ago

ALDX

Aldeyra Therapeutics Faces Securities Lawsuit Over Reproxalap Trial Disclosures

Aldeyra (ALDX) said its dry eye drug reproxalap had demonstrated broad-based, rapid-onset activity, consistent safety, and statistically significant, clinically relevant activity across Phase...

6M ago

ALDX

Aldeyra Therapeutics Announces Upcoming Board Member Departure

Aldeyra Therapeutics ( ($ALDX) ) just unveiled an update. On April 20, 2026, Aldeyra Therapeutics, Inc. announced that...

6M ago

ALDX

Aldeyra downgraded to Neutral from Buy at H.C. Wainwright

H.C. Wainwright analyst Matthew Caufield downgraded Aldeyra (ALDX) to Neutral from Buy with a price target of $2,...

7M ago

ALDX

FDA issues Aldeyra CRL saying reproxalap NDA failed to demonstrate efficacy

Aldeyra (ALDX) announced receipt of a complete response letter, or CRL, from the FDA for the new drug...

7M ago

ALDX

137 FAQ

What was Aldeyra Therapeutics’s price range in the past 12 months?

Aldeyra Therapeutics lowest stock price was €0.55 and its highest was €4.84 in the past 12 months.

What is Aldeyra Therapeutics’s market cap?

Aldeyra Therapeutics’s market cap is €34.99M.

When is Aldeyra Therapeutics’s upcoming earnings report date?

Aldeyra Therapeutics’s upcoming earnings report date is May 06, 2027 which is in 192 days.

How were Aldeyra Therapeutics’s earnings last quarter?

Aldeyra Therapeutics released its earnings results on Jul 31, 2026. The company reported -€0.08 earnings per share for the quarter.

Is Aldeyra Therapeutics overvalued?

According to Wall Street analysts Aldeyra Therapeutics’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Aldeyra Therapeutics pay dividends?

Aldeyra Therapeutics does not currently pay dividends.

What is Aldeyra Therapeutics’s EPS estimate?

Aldeyra Therapeutics’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does Aldeyra Therapeutics have?

Aldeyra Therapeutics has 60,326,420 shares outstanding.

What happened to Aldeyra Therapeutics’s price movement after its last earnings report?

Aldeyra Therapeutics reported an EPS of -€0.08 in its last earnings report. Following the earnings report the stock price went down -2.174%.

Which hedge fund is a major shareholder of Aldeyra Therapeutics?

Currently, no hedge funds are holding shares in DE:137

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Aldeyra Therapeutics Stock Smart Score

Underperform

Fundamentals

Return on Equity

-53.14%

Trailing 12-Months

Asset Growth

-44.05%

Trailing 12-Months

Learn more about TipRanks Smart Score

Top Smart Score Stocks >

Company Description

Aldeyra Therapeutics

Aldeyra Therapeutics, Inc., a biotechnology company, discovers and develops therapies designed to treat immune-mediated diseases. Its lead product candidate is reproxalap, a reactive aldehyde species (RASP) modulator, which is in Phase III clinical trial for the treatment of dry eye disease and allergic conjunctivitis; and ADX-2191, a dihydrofolate reductase inhibitor for the treatment of primary vitreoretinal lymphoma and retinitis pigmentosa. The company also develops ADX-629, an orally administered RASP modulator that is in Phase 2 clinical trials for the treatment of COVID-19, atopic asthma, psoriasis, and alcohol intoxication. In addition, it develops preclinical RASP platforms, including ADX 248, ADX 246, and other novel RASP modulators for the treatment of various diseases associated with RASP. The company was formerly known as Aldexa Therapeutics, Inc. and changed its name to Aldeyra Therapeutics, Inc. in March 2014. Aldeyra Therapeutics, Inc. was incorporated in 2004 and is based in Lexington, Massachusetts.

Aldeyra Therapeutics (137) Earnings & Revenues

Historic Earnings Reports

137 Stock 12 Month Forecast

Average Price Target

€1.79

▲(41.69% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"0":"€0","5":"€5","1.25":"€1.25","2.5":"€2.5","3.75":"€3.75"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":1.78534128,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">€1.79</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":1.78534128,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">€1.79</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":1.78534128,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">€1.79</span>\n  </div></div>","useHTML":true}}],"tickPositions":[0,1.25,2.5,3.75,5],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Jan<br/>2026","6":"Apr<br/>2026","9":"Jul<br/>2026","12":"Oct<br/>2026","25":"Oct<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1.12,1.1711800984615386,1.222360196923077,1.2735402953846156,1.3247203938461538,1.3759004923076923,1.4270805907692308,1.4782606892307693,1.5294407876923077,1.580620886153846,1.6318009846153845,1.682981083076923,1.7341611815384614,{"y":1.78534128,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1.12,1.1711800984615386,1.222360196923077,1.2735402953846156,1.3247203938461538,1.3759004923076923,1.4270805907692308,1.4782606892307693,1.5294407876923077,1.580620886153846,1.6318009846153845,1.682981083076923,1.7341611815384614,{"y":1.78534128,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1.12,1.1711800984615386,1.222360196923077,1.2735402953846156,1.3247203938461538,1.3759004923076923,1.4270805907692308,1.4782606892307693,1.5294407876923077,1.580620886153846,1.6318009846153845,1.682981083076923,1.7341611815384614,{"y":1.78534128,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":4.446,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.366,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.459,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.321,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.561,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.777,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.444,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.29,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.41,"date":1780272000000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":2.1,"date":1782864000000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":1.35,"date":1785542400000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":1.27,"date":1788220800000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":1.12,"date":1790812800000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >